Compliant coupling assembly for cartridge coupling of a drug delivery device

Information

  • Patent Grant
  • 9795534
  • Patent Number
    9,795,534
  • Date Filed
    Wednesday, March 4, 2015
    10 years ago
  • Date Issued
    Tuesday, October 24, 2017
    7 years ago
Abstract
An assembly for coupling a drug delivery device to a cartridge is disclosed. Optionally the assembly includes a coupling, for example a cannula, having one end extending toward the cartridge. The cartridge is optionally aligned by a guide. Optionally the cartridge has a limited freedom of movement. The coupling is optionally supported by a mount. In some embodiments, the mount is compliant enough that the end of the coupling that extends toward may move to said limited freedom of movement under a force less than a leak threshold of the connection between the coupler and the cartridge.
Description
CROSS REFERENCE TO RELATED APPLICATION

This application is related to U.S. patent application titled “FLEXIBLY MOUNTED CARTRIDGE ALIGNMENT COLLAR FOR DRUG DELIVERY DEVICE” to the same Applicant and filed on the same day, which is hereby incorporated by reference in its entirety.


BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to a coupling system for a drug cartridge, more particularly, but not exclusively, to a coupling system including a cannula to be inserted through a septum.


U.S. Patent Application Publication No. 20110054400 discloses that, “a piercing member for piercing a membrane may be arranged within a housing and supported by a compliant that may be for allowing articulation of the piercing member relative to the housing in a case where the piercing member is in the membrane and moved relative to the housing.”


U.S. Pat. No. 6,595,960 discloses, “An apparatus and method of providing a flexible needle assembly for use with a medication delivery pen. The flexible needle assembly includes a needle cannula having proximal and distal points and a hub coupled to the needle cannula. The hub includes a flexible roof, or ball-and-socket arrangement, that permits the needle cannula to move about the centerline of the hub. The flexible roof can include one or more concentric ribs to enhance flexibility of the needle cannula about the centerline of the hub.”


U.S. Pat. No. 3,994,295 discloses that, “An adapter device for mounting a hypodermic needle on a syringe barrel consists of two telescoped elements the outer of which is a casing or shell and the inner or which is a resilient tube bonded at opposite ends to a stem adapted for connection to the barrel and a needle mounting member seated over the end of the shell.”


U.S. Patent Application Publication No. 20140083517 discloses “an alignment device for coupling a liquid drug cartridge with a longitudinal cartridge axis and a constricted neck portion with a cap and a pierceable septum distal from the neck portion with an adapter . . . ” “The septum is perpendicular to the cartridge axis. The device comprises an adapter cannula with a longitudinal cannula axis to pierce the septum and a proximal cartridge engagement structure for axial aligned engagement with a distal end section of cartridge body. The device further comprises a distal adapter engagement structure for axial aligned engagement with the adapter. A coupling of the cartridge with the adapter is enabled via the alignment device. The adapter and the cartridge are, during the coupling, aligned by the cartridge engagement structure and the adapter engagement structure, respectively relative to each other such that the longitudinal cartridge axis and the longitudinal cannula axis form a common longitudinal axis.”


U.S. Patent Application Publication No. 20120029431 discloses “A reservoir and straight-line, push-on connector assembly” . . . “for connecting the reservoir and one of a standard Luer line set and a custom Luer line set to any number of infusion pump configurations using a simple straight-line, push-on motion, wherein the push-on connector assembly is provided and configured to secure the line set and reservoir with the infusion pump. One simple straight-line, push-on motion, preferably performed by gripping an expander sleeve, places and secures the reservoir (i.e., locates the reservoir on the x, y, and z axes) in the pump reservoir cavity, and one simple straight-line, pull-off motion releases and removes the reservoir from the pump reservoir cavity. Rotational orientation is not required for connection, pump engagement, or pump function, and any pulling of the tube set will not release the reservoir as the expansion sleeve through which the tube set is routed is not moved from the securing position by tension on the tube set or Luer fitting.”


U.S. Patent Application Publication No. 2013/096509 discloses “A system for a drug delivery device comprising a reservoir holder configured to hold a reservoir, and an alignment interface comprising a main body configured to be coupled to the reservoir. A first alignment feature is provided on the main body. The first alignment feature cooperates with a corresponding alignment feature provided by the reservoir holder such that when the reservoir is inserted into the holder, the first alignment feature cooperates with the corresponding alignment feature provided by the holder so as to rotate the alignment interface and thereby align the alignment interface within the holder. Thus, the reservoir may be aligned within the reservoir holder. The first alignment feature may comprise at least one protrusion provided on the main body of the interface. The system further comprises one or more coding features.”


U.S. Patent Application Publication No. 2013148270 discloses a method and apparatus, “for delivery of a drug to a recipient. In some embodiments, the delivery apparatus may unseal a drug containing reservoir. In some embodiments, the delivery rate may be controlled and/or adjustable. Optionally the apparatus may be disposable. Optionally, the apparatus may have a low profile and/or be wearable and/or attachable to the recipient. Optionally, discharge of the drug and/or unsealing of the reservoir may be driven by a plunger moving parallel to the base of the apparatus. Optionally, the apparatus may release a hypodermic needle into the recipient. Optionally, release of the hypodermic needle may be in a direction non-parallel and/or orthogonal to the direction of movement of the plunger. Optionally, prior to release, the hypodermic needle may be preserved in an aseptic state by a needle opening septum sealing a needle opening. Optionally, upon release, the hypodermic needle may pierce the needle opening septum.”


Additional background art includes Edwin Chan, Yuh-Fun Maa, Ph.D and David Overcashier; Manufacturing Consideration in Developing a Prefilled Syringe—Investigating the Effect of Headspace Pressure; American Pharmaceutical Review, May 8, 2012 and Appendix 3 Measurement of Leakage of Tuberculin Syringes; World Health Organization Monograph Series No. 12; BCG Vaccination, editors Lydia Edwards, Carroll Palmer and Knut Magnus; Tuberculosis Research Office World Health Organization Copenhagen; World Health Organization; Palais Des Nations, Geneva, 1953.


BRIEF SUMMARY OF THE INVENTION

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.


According to an aspect of some embodiments of the invention, there is provided an assembly for coupling a drug delivery device to a cartridge sealed by a septum having a leak threshold force, the apparatus comprising: a cannula having a tip region configured to penetrate the septum, the tip region having a width; a frame including: a guide sized and shaped to secure the cartridge to the frame and a mount attached to the cannula; the mount positioned on the frame so that the tip region of the cannula protrudes through the septum of the cartridge when the cartridge is secured to the frame by the guide; the mount is compliant enough so that a force of less than a leak threshold force of the septum moves the tip region of the cannula transaxially at least distance equal to the width.


According to some embodiments of the invention, the mount is compliant enough so that a force of less than a leak threshold force of the septum moves the tip region of the cannula transaxially at least distance equal to a position deviation tolerance of the septum.


According to some embodiments of the invention, the distance is greater than a movement caused by a flexibility of the frame and the cannula under the leak threshold force.


According to some embodiments of the invention, the mount compensates for a movement of the cannula at a stress level less than a stress then a bending stress of the cannula.


According to some embodiments of the invention, the leak threshold force is 6 N.


According to some embodiments of the invention, the assembly further comprises: a base located on a side of the cannula opposite the tip region, the base inhibiting backwards movement of the tip region.


According to some embodiments of the invention, the base is positioned off axis of the cannula.


According to some embodiments of the invention, the mount is configured to bias movement of the cannula is a particular direction.


According to some embodiments of the invention, the particular direction is parallel to a face of a bevel of a tip of the cannula.


According to some embodiments of the invention, the cannula is bent at an angle ranging between 30 to 80 degrees.


According to some embodiments of the invention, the assembly further comprises: a second end of the cannula connected to a flexible fluid path.


According to some embodiments of the invention, the assembly further includes the cartridge is coupleable to the cannula by a linear movement of the cartridge with respect to the guide.


According to some embodiments of the invention, the compliant mount is flexible.


According to an aspect of some embodiments of the invention, there is provided a method of supplying a drug to a delivery device comprising: loading a cartridge containing the drug into the delivery device piercing a septum with a cannula; opening a flow path between the cannula and an internal fluid path of the drug delivery device; limiting transaxial movement of the septum to less than a first deviation tolerance; and allow transverse movement of a septum interface region of the cannula to adjust to the movement.


According to some embodiments of the invention, the transaxial movements of the cannula are caused by a stress less than a leak threshold of the septum.


According to some embodiments of the invention, the allowing movement is in one direction more than another direction.


According to some embodiments of the invention, the more movement is allowed in the direction opposite a face of a bevel of the cannula than in a direction of the face of a bevel of the cannula.


According to some embodiments of the invention, the more movement is allowed parallel to a direction faced by a bevel of the cannula than in a direction perpendicular thereto.


According to some embodiments of the invention, the allowing movement is less when there is an axial stress against a tip of the cannula than when the cannula not under axial stress.


According to some embodiments of the invention, the method where the allowing movement is elastic.





BRIEF DESCRIPTION THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention.


In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.


In the drawings:



FIGS. 1A-1B are flow chart illustrations of a method of connecting a cartridge to a fluid path of a drug delivery device in accordance with an embodiment of the current invention;



FIG. 2 is a state diagram of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention;



FIG. 3 is a block diagram of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention;



FIG. 4 is perspective illustration of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention;



FIG. 5A is perspective illustration of a system for connecting a cartridge installed into a lower housing a drug delivery device in accordance with an embodiment of the current invention;



FIG. 5B is cross section illustration of a cartridge in accordance with an embodiment of the current invention;



FIG. 6 is perspective illustration of fluid path of a system for connecting a cartridge and a drug delivery device in accordance with an embodiment of the current invention;



FIG. 7 is perspective illustration of the outside of a drug delivery device in accordance with an embodiment of the current invention;



FIG. 8 is cross sectional illustration of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention;



FIG. 9 is perspective illustration of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention; and



FIGS. 10A-10C are schematic illustrations of a system for connecting a cartridge to a drug delivery device in accordance with an embodiment of the current invention.





DESCRIPTION OF THE INVENTION

The present invention, in some embodiments thereof, relates to a coupling system for a drug cartridge, more particularly, but not exclusively, to a coupling system including a cannula to be inserted through a septum.


An aspect of some embodiments of the present invention relates reducing stress on a coupling caused for example by movement of the coupled parts. For example, the coupling may include a cannula puncturing a septum of a cartridge of a drug delivery device. For example a compliant assembly may reduce stress between a cannula and a septum caused by movements of the cartridge. Misfitting and/or relative movement between a drug cartridge and the delivery device may cause relative movement between the cartridge and the coupling. Optionally, when the septum moves, the compliant assembly may permit compensating movement of a septum interface portion of the cannula reducing stress at the interface. In some embodiments, a compliant coupling assembly may allow directionally dependent displacement of the coupling. For example, the tip of the cannula may move transaxially in response to lateral movement of the septum.


In some embodiments, a frame may interconnect, orient and/or position a guide in relation to a compliant coupling assembly. For example, the frame may include a housing of a drug delivery device and/or the guide may include a guide channel in the housing. Optionally, the cartridge includes a septum near a distal end thereof. For example, the septum may be oriented perpendicular to a longitudinal axis of the cartridge (for example the axis may extend from the distal end to the proximal end of the cartridge). The coupling optionally includes cannula, for example a hollow needle oriented longitudinally near the distal end of the guide channel. In some embodiments, the cartridge may be inserted into the channel and/or the cannula (for example a beveled proximal end thereof). The proximal end of the cannula may protrude into the access channel of the cartridge and/or puncture the septum of the cartridge. After puncturing the septum, the hollow of the needle may form a flow path from the inside of the cartridge into an internal flow path of the drug delivery device.


In some embodiments, the flexibility of the mount may allow freedom of movement of the cannula that is directionally dependent. For example, the septum contacting portion of the cannula may have a sideways freedom of movement (for example the tip and/or the septum contacting portion of the cannula may move transaxially a distance ranging between 0 to 1.0 mm or under a side load of 0.6 kg). For example, a base may be provided distal to the cannula, blocking backward movement of the cannula (e.g. distal movements of the tip of the cannula and/or movements of the tip of the cannula away from the septum).


In some embodiments the tolerance of deviation of positioning of the access channel of the cartridge with respect to the housing may range for example between 0 to 5 mm and/or between 5 to 7 mm and/or between 7 to 15 the tolerance of orientation of the access channel with the housing may range for example between 0 to 7 degrees. For example, when the cartridge is engaged with the fitting, the tolerance of deviation of positioning of the access channel of the cartridge with respect to the coupling may range for example between 0 to 1 mm in all directions and the tolerance of orientation of the access channel with the coupling may range for example between 0 to 2 degrees.


In performance tests leaks were found to occur during use of patch injectors. Careful observation revealed that leaks were sometimes caused by stresses between a septum puncturing needle and the septum of the cartridge. These stresses may in some instances cause an elastic stretching and/or plastic deformation and/or tearing producing an opening around the piercing location where fluid may leak from the cartridge. A compliant coupling assembly may reduce the stress and/or the leakage.


Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.


Method of Connecting a Cartridge to a Fluid Path


Referring now to the drawings, FIGS. 1A and 1B illustrate methods of connecting a cartridge to a fluid path of a drug delivery device in accordance with some embodiments of the current invention. The drug is optionally supplied in a drug cartridge. In some embodiments, the cartridge may fit to the drug delivery device with a low precision. For example, there may be clearance and/or the cartridge may move while in the drug delivery device. For example, the cartridge may be inserted in a position that is slightly out of alignment with the drug delivery device. Alternatively or additionally, a coupling may move and/or be out of alignment. In some embodiments, the coupling may be mounted in a way that it can move and/or adjust to compensate for misalignments.


In some embodiments a drug cartridge may be contact 101 a cartridge with a misalignment between the cartridge and the coupling. For example, the cartridge may have an access channel sealed by a septum on the distal end thereof and/or the cartridge may be positioned using a guide. In various embodiments, the septum may be slightly misaligned with the cannula of the device. For example misalignment may result from imprecision in positioning of the septum with respect to the body of the cartridge and/or imprecision in positioning of the channel with respect to the housing and/or imprecision in positioning of the channel with respect to the cannula and/or due to unbalanced forces when inserting the cartridge into the channel and/or other factors. Changes in working forces on the cartridge (for example difference between forcing during insertion, waiting, and/or discharge) may cause a cartridge to move after connection of the coupling (e.g. puncturing of a septum). These and/or other factors (for example the bevel of the point of the cannula) may cause the coupling to connect 104 to the cartridge in a misaligned and/or strained state. The coupling and/or a mounting of the coupling may adjust 108 to relieve the strained state. Adjustment 108 of the coupling and/or the coupling mount may allow the coupling to remain in the strained state without stressing the cartridge interface.


In some embodiments a cartridge may be inserted 105 into a delivery device. Optionally, inserting 105 the cartridge into the device may connect 103 a coupling and/or open a path between the drug delivery device and the cartridge. Optionally, the path may be used to supply the drug to the delivery device. For example opening a path between the cartridge and delivery device may include opening a fluid flow path allowing flow of a liquid drug from the cartridge to the delivery device. For example the fluid path may be supplied from the access channel of the cartridge to the coupling of the delivery device.


In some embodiments, parts of the injector may move 106 after the path is opened between the delivery device and the cartridge. For example, a plunger may be pushed into the cartridge to push out the contents. The force of the plunger may cause movement 106 (for example movement of the cartridge and/or the access channel with respect to the housing and/or rotation of the cartridge). For example, the angle between the axis of the cartridge and the guide channel of the delivery device may change. Changes in position of the cartridge may sometime cause transaxial movement of the septum and/or access channel. For example, a cartridge may rotate around its axis. In some cases, a connection between a coupling and the cartridge may be off axis and/or off center. Movement 106 of the cartridge may cause strain 107 on coupling-cartridge interface. Optionally, the coupling may compensate 108, for example by moving along with the cartridge and/or the access channel. An adjustable, flexible, and/or conformable coupling mount optionally preserves the integrity of the flow path and/or preserves the flow path in an open state.


In some embodiments, a septum and/or an axis channel may be moved 106 transaxially a distance that is less than or equal to a movement allowed by a position deviation tolerance of a cartridge guide. Stress on the interface between the septum and the tip region of cannula may develop. The stress may cause compensating movements by the cannula. For example, compensating movements of a magnitude of the position deviation tolerance of the septum may be produced by a stress less than the leak threshold force of the septum. For example, the movement deviation tolerance of the septum in the transaxial direction may range between 0 to 0.5 mm and/or 0.5 to 1.5 mm and/or 1.5 to 3 mm and/or 3 to 6 mm. The threshold leakage force on the septum may for example range between 0.1 to 1 N and/or between 1 N to 5 N and/or between 5 N and/or between 5 to 8 N and/or between 8 to 20 N.


In some embodiments, preserving the flow path may include preserving alignment between the coupling and the access channel. In some embodiments, compensation for the movement of the cartridge may include reducing stress between at an interface between the coupling and the cartridge. In some embodiments, preserving integrity of a flow path and/or reducing stress may reduce and/or prevent leakage of the contents of the cartridge.


States of a Compliant Coupling System



FIG. 2 is a state diagram illustrating states of a compliant cartridge coupling assembly in accordance with an embodiment of the current invention. Optionally a coupling assembly may include a compliant mount for a fluid path coupling to an access channel of a cartridge. Optionally, the coupling assembly may compensate for misalignments of one or more parts of the fluid train. For example, the compliant coupling assembly may reduce stress forces on a system under strain. In some embodiments, strain may be caused by misalignment of the cartridge and/or the coupling. For example, the compliant coupling assembly may compensate for misalignment due to machining impressions in the cartridge and/or the housing of the drug delivery device and/or the coupling. Alternatively or additionally, the compliant coupling assembly may compensate for strain caused by changes in alignment due to movement of parts over time.


In some embodiments, a cartridge coupling assembly and/or a cartridge may be connected 262′ and/or may be properly aligned 266 without compensation. Connection of the cartridge to a coupling assembly may include for example insertion of the cartridge into a guide in the housing of a drug delivery device. For example, a cartridge may be aligned 266 to a housing of the device and/or a coupling may be aligned 264 to the cartridge and/or the cartridge guide and/or the housing of the device and/or the mount may be aligned 268d with the housing of the device and/or the guide and/or the cartridge.


In some embodiments, compliance (for example flexing and/or pivoting and/or sliding) of the mount of a coupling may compensate 268b for a misalignment 264′ of the coupling (for example due to manufacturing imprecision of the coupling and/or the mount and/or the frame).


In some embodiments, flexing of a coupling mount may compensate 268a, for a misalignment 266′ and/or movement of a cartridge with respect to a housing of the drug delivery device. Alternatively or additionally, compliance of the mount may compensate 268a, 268c for a misalignment 266′ and/or movement of a cartridge with respect to a housing of the drug delivery device.


In some embodiments, a drug cartridge may be supplied disconnected 262 from a drug delivery device. Optionally or alternatively, the cartridge and the device may be integrally manufactured.


A Compliant Coupling Assembly



FIG. 3 is a block diagram illustrating a compliant coupling assembly in accordance with an embodiment of the current invention. In some embodiments, a housing 310 of a drug delivery device includes a guide 324 for positioning a drug supply cartridge 322 and/or a base 312 supporting a coupling 316. Coupling 316 optionally provides material transport between cartridge 322 and the drug delivery device for example through an internal fluid path 326 of the delivery device. Optionally, coupling 316 may be configured to open a seal 320 (for example seal 320 may include a septum blocking access channel 321). A misalignment between coupling 316 and cartridge 322 and/or movement of cartridge 322 with respect to coupling 316 may cause a disconnection and/or a blockage and/or a leakage. For example, misalignment may be caused by defects in some or all of the parts and/or rough handling of the device. For example the system may include compliant mount 314 supporting coupling 316. Mount 314 may orient coupling 316 with respect to the cartridge. Mount 314 may align and/or position orient coupling 316 with respect to the cartridge 322 and/or an access channel 321 of cartridge 322 and/or guide 324. Mount 314 may be compliant such that coupling 316 may move with respect the cartridge. Optionally fluid path 326 may contain flexible and/or movable components.


In some embodiments, the design of base 312 and/or mount 314 may allow movement of coupling 316 more in one direction than in another. For example, coupling 316 may be allowed to rotate and/or move relatively freely perpendicular to an axis of cartridge 322 and/or guide 324 and/or coupling 316 and/or access channel 321. Movements of coupling 316 toward or away from guide 324 in the direction of a longitudinal axis of axis of cartridge 322 and/or guide 324 and/or coupling 316 and/or access channel 321 may for example be more limited. For example, liming longitudinal movement of coupling 316 may make it easier to connect coupling 316 to access channel 321 and/or cartridge 322, for example when inserting cartridge 322 into the device.


Embodiment for Piercing a Septum of a Cartridge



FIG. 4 is a close up dorsal perspective view of a compliant coupling system for a drug delivery device in accordance with an embodiment of the present invention. In the exemplary embodiment of FIG. 4, the coupling system of a drug delivery device includes a cannula 416. In the exemplary embodiment of FIG. 3, the access channel of the cartridge includes an access channel 521 that for example ranges between 1.8 to 2.2 mm wide (see for example FIG. 5B) sealed by a septum 420. Cannula 416 is supported by a mount 414. Optionally mount 414 is flexible. Alternatively or additionally the distal end of mount 414 is supported on housing 410 of the drug delivery device by a pivoting connection to a base 412.


In some embodiment, a coupling may move more freely in one direction than another. For example, base 412 limits longitudinal movement of cannula 416. For example, longitudinal movement of cannula 416 may be limited to a range between 0 and 1 mm. In some embodiments, limiting longitudinal movement cannula 416 may make it easier to insert cannula 416 through septum 420. In some embodiments, pivoting of mount 414 around base may allow transaxial movement (for example lateral movement and/or upward [dorsal] and/or downward [ventral] movement) of the proximal end 418 and/or a septum interface region 417 of coupling 416. For example transaxial movement may range between 0.1 mm and 0.7 mm. For example, when septum 420 moves, stress between the septum and the tip region of cannula 416 may cause compensating movements of the tip region of cannula 416 (for example the tip region may include a tip 418 and/or a septum interface region 417 of cannula 416). For example, a transaxial movement of the septum of 0.7 mm or less may produce a stress on region 417 of the cannula. The stress may produce compensating movement which reduces the stress. For example, compensating movement of region 417 of 0.7 mm may be produced by a stress of less than the leak threshold force of the septum. For example the leak threshold force of the septum may range between 5 to 7 N. Alternatively or additionally the test leak threshold force may be defined under a test pressure for example ranging between 1 to 5 kg/cm2 and/or between 5 to 6 kg/cm2 and/or between 6 to 12 kg/cm2. Alternatively the leak volume may range for between 0.01 to 0.05 ml and/or between 0.05 to 0.1 ml and/or between 0.1 to 0.2 ml and/or between 0.2 to 0.5 ml and/or between 0.5 to 1 ml. The leak volume may be defined over a given time (for example the volume may leak out over a time ranging between 0 and 60 seconds and/or between 1 to 10 minutes and/or between 10 minutes to an hour and/or between an hour to a day). A leak threshold strain may be defined for example as a quantity of movement of a cannula puncturing a septum that causes leaking between the cannula and the septum, for example leakage of more than 0.05 ml under working conditions. Alternatively or additionally the test leak threshold strain may be defined under a test pressure for example ranging between 1 to 5 kg/cm2 and/or between 5 to 6 kg/cm2 and/or between 6 to 12 kg/cm2. Alternatively the leak volume may range for between 0.01 to 0.05 ml and/or between 0.05 to 0.1 ml and/or between 0.1 to 0.2 ml and/or between 0.2 to 0.5 ml and/or between 0.5 to 1 ml.


In some embodiments, mount 414 may be configured to allow more movement under some conditions than others. For example, mount 416 is configured to inhibit more transaxial movement when there is a longitudinal force in the proximal direction on mount 414. For example, when there is no distal force, mount 414 sits on base 412 and may pivot relatively freely. A distal force (for example the force of septum 420 being pushed against cannula 416 optionally pushes the rear (distal) portion of mount 414 against the rear (distal) wall of housing 410. When braced against the rear wall of housing 410, mount 414 is more stable. In some embodiments, added stability under a distal force may make it easier to puncture septum 420 with cannula 416. Alternatively or additionally, base 412 may be located off the center axis of mount 414. For example, base 412 may be offset slightly (rightward on the page of FIG. 5A) away from the bending direction of cannula 416 to offset the natural tendency of cannula 416 to twist away from its bent leg under distal forces. For example, base 412 may be offset slight in the ventral direction (into the page of FIG. 5A) such that under distal forces, base 412 offsets the tendency of cannula 416 to twist ventrally opposite the dorsal orientation of the face of the bevel of tip 418. Optionally when there is no distal force the slight axial offset of the positioning of base 412 may have a negligible biasing effect on movement of cannula 416. Alternatively or additionally, a channel 413 may be configured to bias the movements of cannula 416. For example, channel 413 in which cannula 416 is supported is open in the dorsal direction. Optionally the open dorsal face of channel 413 allows more freedom of movement to cannula 416 in the dorsal direction.


In some embodiments, cannula 416 may include a hollow bore needle ranging between 10 to 34 gauge. Mount 414 may be made for example of a hard plastic or resin for example Polycarbonate. Alternatively mount 414 may be made of a more flexible material for example an elastomer, for example thermoplastic elastomer (TPC) and/or rubber and/or silicone. In some embodiments the mount may be connected to a frame (e.g. housing 410) on a movable support for example a pivot and/or a sliding support. Movement of the movable support optionally supplies the compliance of the mount. In some embodiments, the length of the axis channel (for example the neck of the cartridge) may range between 6 and 10 mm. For example the diameter of the axis channel (for example the neck of the cartridge) may range between 4 to 8 mm and/or between 8 to 8.5 mm and/or between 8.5 to 9 mm and/or between 9 to 10 mm and/or between 10 to 20 mm.


In some embodiments, an internal fluid path connecting the coupling to a delivery subassembly may include a flexible section. For example, an internal fluid path of the embodiment of FIG. 4 connects a coupling to a patient interface, for example a needle insertion assembly 432. The fluid path optionally includes a flexible tube 426. In some embodiments, the flexibility of tube 426 allows the couple to move without large resistance from and/or breakage of the fluid path. Optionally the tube may be made for example of Silicone or Tygon. The length of the tube may range for example between 10 to 100 mm. The inner diameter of the tube may range for example between 0.1 to 3 mm.


In some embodiments, a cartridge may be steadied by supports. For example, when cartridge 422 is inserted fully into guide channel 424 (into a loaded position) supports 430a and 430b may steady an adapter fitting 419 of cartridge 422. Steadying the position of adapter fitting 419 may increase the precision of positioning and/or decrease movement of channel 521.



FIG. 5A is a dorsal perspective view of a compliant coupling assembly inside an open drug delivery device in accordance with an embodiment of the present invention. In FIG. 5A, the proximal side of mount 414 can be seen protruding through a hole in a cartridge support 530. The proximal portion of cannula 416 is seen extending proximally from mount 414. Optionally the proximal end of cannula 416 includes a sharpened tip 418. In some embodiments, mount 414 is flexible. Flexibility of mount 414 optionally adds a degree of freedom to the system. For example, flexibility of mount 414 may reduce forces on the interface between the delivery device and the cartridge (for example septum 420) caused by bending of cannula 416 and/or misalignment of mount 414 and housing 410 and/or misalignment of septum 420 and fitting 419.


In some embodiments, supports may align a cartridge in a drug delivery device. Optionally support 530 which aligns cartridge 422 also holds compliant mount 414. Optionally, a slack (for example a space between support 530 fitting 419) allows a limited freedom of movement of cartridge 422 with respect to housing 410, for example ranging between 0.01 mm and 1.0 mm. Optionally mount 414 may give a freedom of movement to a proximal portion of cannula 416. For example the freedom of movement may be in the horizontal direction and/or the vertical direction and/or there may be a greater freedom of movement in one direct than the other. For example, the freedom of movement may be to the portion of cannula 416 extending proximally to mount 414 and/or to septum interface portion 417 of the needle and/or the proximal tip 418 of the needle. The freedom of movement may range between 30 to 60% of the freedom of movement of cartridge 422 and/or between 60 to 120% and/or between 120% and 200% to the freedom of movement of cartridge 422 and/or channel 521.


In some embodiments, cannula 416 may include a bent needle, a proximal side of which couples to cartridge 422 (for example by piercing septum 420) and a distal side of which is connected to an internal fluid path (for example flexible tube 426) and/or to an output assembly such as needle insertion assembly 432. Mount 414 optionally includes a curved channel 413 through which fits the bent portion of cannula 416. Optionally, cannula 416 may be bent between 30 to 80 degrees.


In some embodiments, cartridge 422 is inserted into a distal opening in guide channel 424. Optionally, cartridge 422 slides longitudinally along channel 424 until it reaches a loaded position. For example in the loaded position, the coupling (e.g. cannula 426) engages the access channel of cartridge 422, for example by puncturing septum 420 and/or sliding into channel 521 (e.g. see FIG. 5B). An optional locking latch 536 locks cartridge 422 into guide channel 424. For example latch 536 blocks outward movement of a flange 537 on the proximal end of cartridge 422.



FIG. 5B is a cross sectional view of a drug cartridge for a drug delivery device in accordance with an embodiment of the present invention. The cross section view of cartridge 422 illustrates for example a narrowed access channel 521 of cartridge 422. An exemplary plunger 570 is illustrated near the proximal end of cartridge 422. Cartridge 422 optionally includes a distal flange 537.



FIG. 6 is a distal view of a compliant coupling assembly in accordance with an embodiment of the current invention. FIG. 6 further illustrates details of needle insertion assembly 432 which optionally includes a bent needle 616 (for example a hypodermic needle for insertion into a patient) connected to tube 426 and/or a mount 614 with a curved channel.



FIG. 7 is a proximal/dorsal perspective view of the exterior of a delivery device including compliant coupling assembly in accordance with an embodiment of the present invention. The compliant coupling assembly is seen through a window 738 in an upper housing section 710 of the injector. An optionally activation button 774 is shown.



FIG. 8 is a distal cross sectional view (cut along a horizontal plane passing through the middle of cartridge 422 and/or cannula 416) of a compliant coupling assembly of a drug cartridge in a loaded position in accordance with an embodiment of the present invention. Optionally, the in loaded position, cannula 416 has been inserted through septum 420 into channel 521. Optionally cannula 416 forms a fluid path from the inside of cartridge 422 to tube 426.



FIG. 9 is a proximal perspective view compliant coupling assembly to an access channel of a drug cartridge installed in a delivery device in accordance with an embodiment of the present invention. For example, in the embodiment of FIG. 9, the coupling of the compliant coupling assembly includes a septum 920. Optionally in the exemplary embodiment of FIG. 9 the cartridge includes a cannula for piercing septum 920. In some embodiment, septum 920 may be mounted on a compliant mount 914. Optionally, compliant mount 914 allows a defined freedom of transaxial movement to septum 920. For example, the compliance of mount 914 may compensate for transaxial movements and/or rotation of cartridge 922 and/or needle 916. For example, mount 914 may compensating for transaxial movement of needle 916 without stressing the interface between the needle 916 beyond a leak threshold stress on septum 920. A support 930 connected for example to a slit in the side of mount 914 and/or a base 912 distal to mount 914 may limit longitudinal movements of septum 920. For example, limiting longitudinal movements may make it easier to pierce septum 920 with cannula 916.



FIGS. 10A-10C illustrate a proximal close up perspective view of a compliant coupling assembly in accordance with an embodiment of the current invention. In some embodiments, a compliant mount 1014 holds a coupler including a cannula 1016. Optionally, when cannula 1016 pierces septum 1020, the beveled tip 1018 may be translated transaxially. For example in FIG. 10B cannula 1016 is oriented with the bevel of tip 1018 facing upward (dorsally). In some cases, when tip 1018 penetrates septum 1020 it for a hole off center. For example, for a beveled tip, a hole is formed at the point of the needle which may be located off the axis of the needle by half the width of the cannula. Alternatively or additionally, when the cannula is directed at an angle to the direction of movement between the septum and the cannula, a hole may be produced off the axis. In the example of FIGS. 10A-10C, the beveled tip 1018 of cannula 1016 is located off center (e.g. below and/or ventral) to the axis of cannula 1016 by half the width (e.g. diameter) of cannula 1016. As cannula 1016 is inserted through the off axis hole, cannula 1016 is deflected downward (e.g. ventrally) for example as illustrated in FIGS. 10B and 10C.


In some embodiments, a cannula may be inserted through a septum until a septum interface region intersects the septum. For example, FIG. 10C illustrates cannula 1016 positioned with septum interface region 1017 intersecting septum 1020. For example, septum interface region 1017 may be located 3.5 mm from tip 1018 of cannula 1016 and/or 2.5 mm from the proximal point of connection between cannula 1016 and mount 1014. For example a rigid mount and steel cannula may produce a force due to the deflection and/or bending of the cannula that is greater than the leak threshold of septum 1020. For example, a septum leak threshold force of the septum may range between 6 to 7 N. In some cases forces greater than the leak threshold may result in tearing of the septum in the direction of the bevel and/or leaking of the septum from behind the bevel. Optionally, compliant mount 1014 may allow deflection of septum interface region with less stress than the bending stress of the cannula and/or a septum leak threshold. For example, compensating movement and/or flexing of mount 1014 may avoid producing a tear and/or leak in septum 1020.


In some embodiments, a cartridge may rotate around its longitudinal axis. For example this may cause septum 1020 to rotate. In some cases, for the example of FIGS. 10A-10C where cannula has punctured septum 1020 off center) such rotation may cause twisting of cannula 1016. Compliant mount 1014 may be configured to allow such twisting without producing a force greater than a leakage threshold between septum interface region 1017 of cannula 1016 and septum 1020.


It is expected that during the life of a patent maturing from this application many relevant technologies will be developed and the scope of the terms are intended to include all such new technologies a priori.


As used herein the term “about” refers to ±5%.


The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.


The term “consisting of” means “including and limited to”.


The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.


As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.


Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.


Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.


It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.


Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.


All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

Claims
  • 1. An assembly for coupling a drug delivery device to a cartridge sealed by a septum, the assembly comprising: an axially extending cannula having a tip region configured to penetrate the septum, said tip region having a width; anda frame including:an axially extending guide sized and shaped to secure the cartridge to said frame; anda mount pivotably positioned on said frame, the cannula being attached to said mount such that said tip region of said cannula protrudes through the septum of the cartridge when said cartridge is secured to said frame by said guide;wherein a requisite degree of movement between the cannula and the septum at an interface therebetween to cause leakage at the interface defines a leak threshold force of the septum, andwherein said mount permits transaxial movement of said tip region of said cannula by at least a distance equal to the width of the tip region in response to a force applied to the cannula at the interface between the cannula and the septum of less than the leak threshold force.
  • 2. The assembly of claim 1, wherein a force of less than a leak threshold force of said septum moves said tip region of said cannula transaxially at least a distance equal to a position deviation tolerance of said septum.
  • 3. The assembly of claim 1, wherein said distance is greater than a movement caused by a flexibility of said frame and said cannula under said leak threshold force.
  • 4. The assembly of claim 1, wherein said mount compensates for a movement of said cannula at a stress level less than a bending stress of said cannula.
  • 5. The assembly of claim 1, wherein said leak threshold force is 6 N.
  • 6. The assembly of claim 1, further comprising: a base located on a side of said cannula opposite said tip region, said base inhibiting backwards movement of said tip region.
  • 7. The assembly of claim 6, wherein said base is positioned off axis of said cannula.
  • 8. The assembly of claim 1, wherein said mount is configured to bias movement of said cannula in a particular direction.
  • 9. The assembly of claim 8, wherein said particular direction is parallel to a face of a bevel of a tip of said cannula.
  • 10. The assembly of claim 1, wherein said cannula is bent at an angle ranging between 30 to 80 degrees.
  • 11. The assembly of claim 1, wherein a second end of said cannula is connected to a flexible fluid path.
  • 12. The assembly of claim 1, wherein the cartridge is coupleable to said cannula by a linear movement of the cartridge with respect to the guide.
  • 13. The assembly of claim 1, wherein said compliant mount is flexible.
US Referenced Citations (412)
Number Name Date Kind
3994295 Wulff Nov 1976 A
4601702 Hudson Jul 1986 A
4886499 Cirelli et al. Dec 1989 A
4919596 Slate et al. Apr 1990 A
4950246 Muller Aug 1990 A
5097122 Colman et al. Mar 1992 A
5109850 Blanco et al. May 1992 A
5131816 Brown et al. Jul 1992 A
5211638 Dudar et al. May 1993 A
5254096 Rondelet et al. Oct 1993 A
5383865 Michel Jan 1995 A
5501665 Jhuboo et al. Mar 1996 A
5593390 Castellano et al. Jan 1997 A
5616132 Newman Apr 1997 A
5643218 Lynn et al. Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5690618 Smith et al. Nov 1997 A
D393314 Meisner et al. Apr 1998 S
5800420 Gross et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5814020 Gross Sep 1998 A
5851197 Marano et al. Dec 1998 A
5858001 Tsals et al. Jan 1999 A
5858008 Capaccio Jan 1999 A
5931814 Alex et al. Aug 1999 A
5957895 Sage et al. Sep 1999 A
5993423 Choi Nov 1999 A
6004297 Steenfeldt-Jensen et al. Dec 1999 A
6064797 Crittendon et al. May 2000 A
6074369 Sage et al. Jun 2000 A
6186982 Gross et al. Feb 2001 B1
6200289 Hochman et al. Mar 2001 B1
6248093 Moberg Jun 2001 B1
6277095 Kriesel et al. Aug 2001 B1
6277098 Klitmose et al. Aug 2001 B1
6277099 Strowe et al. Aug 2001 B1
6287283 Ljunggreen et al. Sep 2001 B1
6362591 Moberg Mar 2002 B1
6391005 Lum et al. May 2002 B1
6423029 Elsberry Jul 2002 B1
D465026 May et al. Oct 2002 S
6458102 Mann et al. Oct 2002 B1
6485461 Mason et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6500150 Gross et al. Dec 2002 B1
6517517 Farrugia et al. Feb 2003 B1
D471274 Diaz et al. Mar 2003 S
D471983 Hippolyte et al. Mar 2003 S
6555986 Moberg Apr 2003 B2
6558351 Steil et al. May 2003 B1
6589229 Connelly et al. Jul 2003 B1
6595956 Gross et al. Jul 2003 B1
6595960 West et al. Jul 2003 B2
6645181 Lavi Nov 2003 B1
6652482 Hochman Nov 2003 B2
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6659980 Moberg et al. Dec 2003 B2
6673033 Sciulli et al. Jan 2004 B1
6679862 Diaz et al. Jan 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6749587 Flaherty Jun 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6786890 Preuthun et al. Sep 2004 B2
6800071 McConnell et al. Oct 2004 B1
6805687 Dextradeur et al. Oct 2004 B2
6817990 Yap et al. Nov 2004 B2
6824529 Gross et al. Nov 2004 B2
6843782 Gross et al. Jan 2005 B2
6854620 Ramey Feb 2005 B2
6905298 Haring Jun 2005 B1
6908452 Diaz et al. Jun 2005 B2
6960192 Flaherty et al. Nov 2005 B1
7001360 Veasey et al. Feb 2006 B2
7048715 Diaz et al. May 2006 B2
7060059 Keith et al. Jun 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
7193521 Moberg et al. Mar 2007 B2
D544092 Lewis Jun 2007 S
7247149 Beyerlein Jul 2007 B2
7247150 Bierman Jul 2007 B2
7250037 Shermer et al. Jul 2007 B2
7267669 Staunton et al. Sep 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7384413 Gross et al. Jun 2008 B2
7390314 Stutz, Jr. et al. Jun 2008 B2
7407493 Cane′ Aug 2008 B2
7455663 Bikovsky Nov 2008 B2
7465290 Reilly Dec 2008 B2
7497842 Diaz et al. Mar 2009 B2
7530964 Lavi et al. May 2009 B2
7547281 Hayes et al. Jun 2009 B2
7565208 Harris et al. Jul 2009 B2
7569050 Moberg et al. Aug 2009 B2
D600341 Loerwald Sep 2009 S
7585287 Bresina et al. Sep 2009 B2
7588559 Aravena et al. Sep 2009 B2
D602155 Foley et al. Oct 2009 S
D602586 Foley et al. Oct 2009 S
D604835 Conley Nov 2009 S
7621893 Moberg et al. Nov 2009 B2
7628770 Ethelfeld Dec 2009 B2
7628772 McConnell et al. Dec 2009 B2
7628782 Adair et al. Dec 2009 B2
7637891 Wall Dec 2009 B2
7641649 Moberg et al. Jan 2010 B2
7660627 McNichols et al. Feb 2010 B2
7678079 Shermer et al. Mar 2010 B2
7682338 Griffin Mar 2010 B2
7686787 Moberg et al. Mar 2010 B2
7699829 Harris et al. Apr 2010 B2
7699833 Moberg et al. Apr 2010 B2
7704227 Moberg et al. Apr 2010 B2
7704231 Pongpairochana et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7713238 Mernoe May 2010 B2
7713240 Istoc et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7717913 Novak et al. May 2010 B2
7722574 Toman et al. May 2010 B2
7736344 Moberg et al. Jun 2010 B2
7744589 Mounce et al. Jun 2010 B2
7749194 Edwards et al. Jul 2010 B2
7766873 Moberg et al. Aug 2010 B2
7776030 Estes et al. Aug 2010 B2
7780637 Jerde et al. Aug 2010 B2
7789857 Moberg et al. Sep 2010 B2
7801599 Young et al. Sep 2010 B2
7806868 De Polo et al. Oct 2010 B2
7815622 Istoc et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7837659 Bush, Jr. et al. Nov 2010 B2
7846132 Gravesen et al. Dec 2010 B2
7857131 Vedrine Dec 2010 B2
7879025 Jacobson et al. Feb 2011 B2
7879026 Estes et al. Feb 2011 B2
7892206 Moberg et al. Feb 2011 B2
7918825 O'Connor et al. Apr 2011 B2
7918843 Genosar et al. Apr 2011 B2
7935104 Yodfat et al. May 2011 B2
7935105 Miller et al. May 2011 B2
7938803 Mernoe et al. May 2011 B2
7955297 Radmer et al. Jun 2011 B2
7955305 Moberg et al. Jun 2011 B2
7967784 Pongpairochana et al. Jun 2011 B2
7967795 Cabiri Jun 2011 B1
7981105 Adair et al. Jul 2011 B2
7988683 Adair et al. Aug 2011 B2
7993300 Nyholm et al. Aug 2011 B2
7998111 Moberg et al. Aug 2011 B2
7998116 Mernoe Aug 2011 B2
7998117 Gross et al. Aug 2011 B2
8002752 Yodfat et al. Aug 2011 B2
8021357 Tanaka et al. Sep 2011 B2
8025658 Chong et al. Sep 2011 B2
8029459 Rush et al. Oct 2011 B2
8029460 Rush et al. Oct 2011 B2
8029469 Ethelfeld Oct 2011 B2
8034019 Nair et al. Oct 2011 B2
8038648 Marksteiner Oct 2011 B2
8038666 Triplett et al. Oct 2011 B2
8057436 Causey et al. Nov 2011 B2
8062253 Nielsen et al. Nov 2011 B2
8062257 Moberg et al. Nov 2011 B2
8062259 Nycz et al. Nov 2011 B2
8065096 Moberg et al. Nov 2011 B2
8066694 Wagener Nov 2011 B2
D650079 Presta et al. Dec 2011 S
D652503 Cameron et al. Jan 2012 S
8105279 Mernoe et al. Jan 2012 B2
8114046 Covino et al. Feb 2012 B2
8114064 Alferness et al. Feb 2012 B2
8114066 Naef et al. Feb 2012 B2
8147446 Yodfat et al. Apr 2012 B2
8152764 Istoc et al. Apr 2012 B2
8152770 Reid Apr 2012 B2
8152779 Cabiri Apr 2012 B2
8157769 Cabiri Apr 2012 B2
8162923 Adams et al. Apr 2012 B2
8167841 Teisen-Simony et al. May 2012 B2
8172804 Bikovsky May 2012 B2
8182447 Moberg et al. May 2012 B2
8182462 Istoc et al. May 2012 B2
8197444 Bazargan et al. Jun 2012 B1
8206296 Jennewine Jun 2012 B2
8206351 Sugimoto et al. Jun 2012 B2
8221356 Enggaard et al. Jul 2012 B2
8221359 Kristensen et al. Jul 2012 B2
8226607 Carter et al. Jul 2012 B2
8226608 Mernoe Jul 2012 B2
8234769 Leidig Aug 2012 B2
8267893 Moberg et al. Sep 2012 B2
8267921 Yodfat et al. Sep 2012 B2
8287520 Drew et al. Oct 2012 B2
8308679 Hanson et al. Nov 2012 B2
8361028 Gross et al. Jan 2013 B2
8372039 Mernoe et al. Feb 2013 B2
8373421 Lindegger et al. Feb 2013 B2
8409142 Causey et al. Apr 2013 B2
8414557 Istoc et al. Apr 2013 B2
8430847 Mernoe et al. Apr 2013 B2
8469942 Kow et al. Jun 2013 B2
8474332 Bente, IV et al. Jul 2013 B2
8475408 Mernoe et al. Jul 2013 B2
8479595 Vazquez et al. Jul 2013 B2
8483980 Moberg et al. Jul 2013 B2
8495918 Bazargan et al. Jul 2013 B2
8512287 Cindrich et al. Aug 2013 B2
8517987 Istoc et al. Aug 2013 B2
8523803 Favreau Sep 2013 B1
8556856 Bazargan et al. Oct 2013 B2
8574216 Istoc et al. Nov 2013 B2
8603026 Favreau Dec 2013 B2
8603027 Favreau Dec 2013 B2
8617110 Moberg et al. Dec 2013 B2
8628510 Bazargan et al. Jan 2014 B2
8647074 Moberg et al. Feb 2014 B2
8647296 Moberg et al. Feb 2014 B2
8668672 Moberg et al. Mar 2014 B2
8674288 Hanson et al. Mar 2014 B2
8679060 Mernoe et al. Mar 2014 B2
8681010 Moberg et al. Mar 2014 B2
8690855 Alderete, Jr. et al. Apr 2014 B2
8708961 Field et al. Apr 2014 B2
8715237 Moberg et al. May 2014 B2
8753326 Chong et al. Jun 2014 B2
8753331 Murphy Jun 2014 B2
8764707 Moberg et al. Jul 2014 B2
8764723 Chong et al. Jul 2014 B2
8771222 Kanderian, Jr. et al. Jul 2014 B2
8777896 Starkweather et al. Jul 2014 B2
8777924 Kanderian, Jr. et al. Jul 2014 B2
8777925 Patton Jul 2014 B2
8784369 Starkweather et al. Jul 2014 B2
8784370 Lebel et al. Jul 2014 B2
8790295 Sigg et al. Jul 2014 B1
8795224 Starkweather et al. Aug 2014 B2
8795231 Chong et al. Aug 2014 B2
8795260 Drew Aug 2014 B2
8801668 Ali et al. Aug 2014 B2
8808269 Bazargan et al. Aug 2014 B2
8810394 Kalpin Aug 2014 B2
8864739 Moberg et al. Oct 2014 B2
8870818 Alderete, Jr. et al. Oct 2014 B2
8992475 Mann et al. Mar 2015 B2
9011371 Moberg et al. Apr 2015 B2
9033924 Yavorsky May 2015 B2
9050406 Kow et al. Jun 2015 B2
20010034502 Moberg et al. Oct 2001 A1
20020040208 Flaherty et al. Apr 2002 A1
20020055711 Lavi et al. May 2002 A1
20030135159 Daily et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030171717 Farrugia et al. Sep 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040085215 Moberg et al. May 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050065472 Cindrich et al. Mar 2005 A1
20050071487 Lu et al. Mar 2005 A1
20050171487 Haury et al. Aug 2005 A1
20050171512 Flaherty Aug 2005 A1
20050177136 Miller Aug 2005 A1
20050197650 Sugimoto et al. Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20060095014 Ethelfeld May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060173439 Thorne et al. Aug 2006 A1
20060184154 Moberg et al. Aug 2006 A1
20060229569 Lavi et al. Oct 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060283465 Nickel et al. Dec 2006 A1
20070021733 Hansen et al. Jan 2007 A1
20070049865 Radmer et al. Mar 2007 A1
20070118405 Campbell et al. May 2007 A1
20070149926 Moberg et al. Jun 2007 A1
20070191770 Moberg et al. Aug 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080033369 Kohlbrenner et al. Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080059133 Edwards et al. Mar 2008 A1
20080140006 Eskuri et al. Jun 2008 A1
20080140018 Enggaard et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080167641 Hansen et al. Jul 2008 A1
20080188813 Miller et al. Aug 2008 A1
20080215006 Thorkild Sep 2008 A1
20080221522 Moberg et al. Sep 2008 A1
20080221523 Moberg et al. Sep 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080275425 Strickler et al. Nov 2008 A1
20080294143 Tanaka et al. Nov 2008 A1
20080306449 Kristensen et al. Dec 2008 A1
20080312601 Cane Dec 2008 A1
20080319416 Yodfat et al. Dec 2008 A1
20090054750 Jennewine Feb 2009 A1
20090076453 Mejlhede et al. Mar 2009 A1
20090088694 Carter et al. Apr 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093792 Gross et al. Apr 2009 A1
20090124977 Jensen May 2009 A1
20090149830 Spector Jun 2009 A1
20090182277 Carter Jul 2009 A1
20090234319 Marksteiner Sep 2009 A1
20090240240 Hines et al. Sep 2009 A1
20090253973 Bashan et al. Oct 2009 A1
20090259176 Yairi Oct 2009 A1
20090299397 Ruan et al. Dec 2009 A1
20090326509 Muse et al. Dec 2009 A1
20100030156 Beebe et al. Feb 2010 A1
20100030198 Beebe et al. Feb 2010 A1
20100037680 Moberg et al. Feb 2010 A1
20100049144 McConnell et al. Feb 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100076412 Rush et al. Mar 2010 A1
20100094255 Nycz et al. Apr 2010 A1
20100100076 Rush et al. Apr 2010 A1
20100100077 Rush et al. Apr 2010 A1
20100106098 Atterbury et al. Apr 2010 A1
20100121314 Iobbi May 2010 A1
20100137790 Yodfat Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100162548 Leidig Jul 2010 A1
20100168607 Miesel Jul 2010 A1
20100198157 Gyrn et al. Aug 2010 A1
20100204657 Yodfat et al. Aug 2010 A1
20100212407 Stringham et al. Aug 2010 A1
20100217192 Moberg et al. Aug 2010 A1
20100217193 Moberg et al. Aug 2010 A1
20100234830 Straessler et al. Sep 2010 A1
20100241065 Moberg et al. Sep 2010 A1
20100264931 Lindegger et al. Oct 2010 A1
20100274112 Hoss et al. Oct 2010 A1
20100274192 Mernoe Oct 2010 A1
20100280499 Yodfat et al. Nov 2010 A1
20100331826 Field et al. Dec 2010 A1
20110034900 Yodfat et al. Feb 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110054400 Chong et al. Mar 2011 A1
20110066131 Cabiri Mar 2011 A1
20110119033 Moberg et al. May 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160666 Hanson et al. Jun 2011 A1
20110160669 Gyrn et al. Jun 2011 A1
20110172645 Moga et al. Jul 2011 A1
20110178472 Cabiri Jul 2011 A1
20110201998 Pongpairochana et al. Aug 2011 A1
20110224614 Moberg et al. Sep 2011 A1
20110238031 Adair et al. Sep 2011 A1
20110245773 Estes et al. Oct 2011 A1
20110264383 Moberg et al. Oct 2011 A1
20110270160 Mernoe Nov 2011 A1
20110282282 Lorenzen et al. Nov 2011 A1
20110295205 Kaufmann et al. Dec 2011 A1
20110313238 Reichenbach et al. Dec 2011 A1
20110319861 Wilk Dec 2011 A1
20110319919 Curry et al. Dec 2011 A1
20120004602 Hanson et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120022499 Anderson et al. Jan 2012 A1
20120025995 Moberg et al. Feb 2012 A1
20120029431 Hwang et al. Feb 2012 A1
20120035546 Cabiri Feb 2012 A1
20120041364 Smith Feb 2012 A1
20120041370 Moberg et al. Feb 2012 A1
20120041414 Estes et al. Feb 2012 A1
20120071828 Tojo et al. Mar 2012 A1
20120078217 Smith et al. Mar 2012 A1
20120096953 Bente, IV et al. Apr 2012 A1
20120096954 Vazquez et al. Apr 2012 A1
20120101436 Bazargan et al. Apr 2012 A1
20120108933 Liang et al. May 2012 A1
20120160033 Kow et al. Jun 2012 A1
20120165733 Bazargan et al. Jun 2012 A1
20120165780 Bazargan et al. Jun 2012 A1
20120215169 Moberg et al. Aug 2012 A1
20120215199 Moberg et al. Aug 2012 A1
20120226234 Bazargan et al. Sep 2012 A1
20120259282 Alderete, Jr. et al. Oct 2012 A1
20120310153 Moberg et al. Dec 2012 A1
20130012873 Gross et al. Jan 2013 A1
20130068319 Plumptre et al. Mar 2013 A1
20130096509 Avery et al. Apr 2013 A1
20130133438 Kow et al. May 2013 A1
20130148270 Fujioka et al. Jun 2013 A1
20130237953 Kow et al. Sep 2013 A1
20130245595 Kow et al. Sep 2013 A1
20130253419 Favreau Sep 2013 A1
20130253420 Favreau Sep 2013 A1
20130253421 Favreau Sep 2013 A1
20130253472 Cabiri Sep 2013 A1
20130331791 Gross et al. Dec 2013 A1
20140055073 Favreau Feb 2014 A1
20140055076 Favreau Feb 2014 A1
20140058349 Bazargan et al. Feb 2014 A1
20140083517 Moia Mar 2014 A1
20140094755 Bazargan et al. Apr 2014 A1
20140128807 Moberg et al. May 2014 A1
20140128835 Moberg et al. May 2014 A1
20140135692 Alderete, Jr. et al. May 2014 A1
20140135694 Moberg et al. May 2014 A1
20140142499 Moberg et al. May 2014 A1
20140148784 Anderson et al. May 2014 A1
20140148785 Moberg et al. May 2014 A1
20140163522 Alderete, Jr. et al. Jun 2014 A1
20140194819 Maule et al. Jul 2014 A1
20140207064 Yavorsky Jul 2014 A1
20140207065 Yavorsky Jul 2014 A1
20140207066 Yavorsky Jul 2014 A1
20140213975 Clemente et al. Jul 2014 A1
20140236087 Alderete, Jr. et al. Aug 2014 A1
20140261758 Wlodarczyk et al. Sep 2014 A1
Foreign Referenced Citations (8)
Number Date Country
0401179 Dec 1990 EP
1249250 Oct 2002 EP
2412395 Feb 2012 EP
2712650 Apr 2014 EP
9009202 Aug 1990 WO
9632975 Oct 1996 WO
2011090955 Jul 2011 WO
2011141907 Nov 2011 WO
Non-Patent Literature Citations (2)
Entry
Extended Search Report dated Jun. 13, 2016 in EP Application No. 16157430.6.
Edwin Chan, Yuh-Fun Maa, Ph.D and David Overcashier; Manufacturing Consideration in Developing a Prefilled Syringe—Investigating the Effect of Headspace Pressure; American Pharmaceutical Review, May 8, 2012 and Appendix 3 Measurement of Leakage of Tuberculin Syringes; World Health Organization Monograph Series No. 12; BCG Vaccination, editors Lydia Edwards, Carroll Palmer and Knut Magnus; Tuberculosis Research Office World Health Organization Copenhagen; World Health Organization; Palais Des Nations, Geneva, 1953.
Related Publications (1)
Number Date Country
20160256352 A1 Sep 2016 US